Mocetinostat
| Structural formula | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||||||||
| General | ||||||||||||||||
| Non-proprietary name | Mocetinostat | |||||||||||||||
| other names |
N - (2-aminophenyl) -4 - [(4-pyridin-3-yl-pyrimidin-2-yl-amino) methyl] benzamide |
|||||||||||||||
| Molecular formula | C 23 H 20 N 6 O | |||||||||||||||
| External identifiers / databases | ||||||||||||||||
|
||||||||||||||||
| Drug information | ||||||||||||||||
| Drug class | ||||||||||||||||
| Mechanism of action |
HDAC inhibitor |
|||||||||||||||
| properties | ||||||||||||||||
| Molar mass | 396.46 g · mol -1 | |||||||||||||||
| safety instructions | ||||||||||||||||
|
||||||||||||||||
| As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . | ||||||||||||||||
Mocetinostat is a histone deacetylase inhibitor that is currently in clinical trials for the treatment of various cancers, such as B. Follicular Lymphoma , Hodgkin Lymphoma, and Acute Myeloid Leukemia .
The dihydrobromide salt is used medicinally .
Mechanism of action
Mocetinostat selectively inhibits histone deacetylases 1, 2, 3 and 11, which leads to hyperacetylation of histones in tumors . This leads to an interruption of the cell cycle , expression of the P21 protein and subsequent apoptosis of the tumor cell .
literature
- Lane AA, Chabner BA: Histone deacetylase inhibitors in cancer therapy . In: Journal of Clinical Oncology . 27, No. 32, November 2009, pp. 5459-5468. doi : 10.1200 / JCO.2009.22.1291 . PMID 19826124 .
- Bonfils C, Kalita A, Dubay M, et al. : Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay . In: Clinical Cancer Research . 14, No. 11, June 2008, pp. 3441-3449. PMID 18519775 .
Individual evidence
- ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
